Novacyt Directors Boost Stakes as Molecular Diagnostics Group Expands Global Reach

Novacyt ( (FR:ALNOV) ) just unveiled an announcement.

Novacyt S.A., a dual-listed molecular diagnostics group specialising in genomic medicine, offers clinical in vitro diagnostics, next-generation DNA sample preparation and PCR platforms, and research-use-only testing and sequencing services for human, veterinary, agricultural and environmental applications. Headquartered near Paris with operations in the UK, North America and Asia-Pacific, the company recently extended its distribution footprint into Australia and the wider region through the acquisition of Southern Cross Diagnostics, strengthening its global reach.

The company disclosed that chief executive Lyn Rees, chairman John Brown and non-executive director Ian Gilham have purchased new ordinary shares on the market, with individual acquisitions ranging from 28,750 to 73,762 shares at around €0.39 or £0.34 per share. The insider buying modestly increases management’s economic exposure, signalling board-level confidence in Novacyt’s prospects as it integrates its latest acquisition and pursues growth in the competitive molecular diagnostics sector.

More about Novacyt

Novacyt S.A. is an international molecular diagnostics company focused on genomic medicine, developing, manufacturing and commercialising molecular assays and instrumentation that provide end-to-end workflows from sample to result. It operates across human health, animal health and environmental sectors through three segments: clinical diagnostics, DNA sample preparation and PCR instrumentation, and research-use-only assay and sequencing services. The group is headquartered in Le Vésinet, France, with offices in the UK, Singapore, the U.S. and Canada, and a commercial presence in over 65 countries, recently expanded in Australia and the wider Asia-Pacific region via the acquisition of Southern Cross Diagnostics. Novacyt’s shares trade on Euronext Growth in Paris and on London’s AIM market, positioning it as a cross-listed player in the global life sciences and diagnostics markets.

For an in-depth examination of ALNOV stock, go to TipRanks’ Overview page.